
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
from FDA,2023.03
Basic Characteristics and Composition of TepotinibTepotinib is a film-coated tablet containing 225 mg of the active ingredient tepotinib. Tepotinib is a prescription drug and must ···【more】
Article source:Lucius LaosRelease date:2026-06-17Recommended:125
Core Mechanism and Indications of TepotinibTepotinib is a precision targeted therapy that works by specifically inhibiting the MET protein, which drives cancer growth. By blocking ···【more】
Article source:Lucius LaosRelease date:2026-06-17Recommended:126
Core Mechanism and Indications of TepotinibTepotinib is a precision targeted therapy that works by specifically inhibiting the MET protein, which drives cancer growth. By blocking ···【more】
Article source:Lucius LaosRelease date:2026-06-15Recommended:145
Non small cell lung cancer with MET gene exon 14 mutation positive and unresectable progression and recurrence.【more】
Article source:Lucius LaosRelease date:2026-01-05Recommended:109

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643